64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
aka PHANTOM
A phase 1/2 trial of 64Cu-LNTH-1363S in sarcomas, oesophageal cancer, gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Lantheus Medical Imaging, now recruiting.
Overview
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer is a phase 1/2 interventional study registered as NCT06298916 by Lantheus Medical Imaging, with 26 participants planned, started 2025-08 and due to reach its primary completion in 2025-11. Interventions recorded: 64Cu-LNTH-1363S.
Setting
A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)
Phase
Phase 1/2
Sponsor
Lantheus Medical Imaging
Registry
Enrolled
26 enrolled
Similar pages
not linked directly; found by shared links- Trial64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- TrialLu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Shares Lantheus and the tag pipeline.
- TrialCopper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Shares Copper-64 and the tag pipeline.
- TrialSafety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
Shares Copper-64 and the tag pipeline.
- CompanyNuclidium
- TechnologySarcophagine chelation
- IdeaA single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment
- CompanyClarity Pharmaceuticals